Anika Therapeutics, Inc. (ANIK) posted a first quarter loss from continuing operations of $3.96 million compared to a loss of $1.96 million, a year ago. Loss from continuing operations per share was $0.28 compared to a loss of $0.13. Adjusted net loss per share was $0.06 compared to profit of $0.13. Adjusted EBITDA was $0.1 million, for the quarter.
First quarter revenue from continuing operations was $26.2 million, a 10% decrease compared to the same period in 2024.
https://www.nasdaq.com/articles/anika-therapeutics-posts-wider-loss-cont-ops-q1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.